Women’s HRT & menopause telehealth
Who prescribes menopause hormone therapy online, and who takes insurance.
5 providers offer this. 0 include labs in the price. 2 accept insurance. Figures reflect what each provider publishes. * = provisional score.
Highest-scored providers
Alloy 10.0 Cash-pay women who want FDA-approved estradiol and progesterone prescribed by a physician through messaging, with prices visible up front.
Read the review → #2 Evernow 8.7Women seeking ongoing menopause care by messaging, with insurance-covered video visits and local-pharmacy prescriptions.
Read the review → #3
Midi Health 8.3* Women with commercial PPO insurance seeking menopause or perimenopause care, including hormone therapy, through video visits.
Read the review →Ranked guides
All providers
| Clinic | Score | Consult | Labs | Prescriber | Insurance | From |
|---|---|---|---|---|---|---|
| Alloy A menopause telehealth provider offering prescription hormone therapy and related treatments through an asynchronous consult. | 10.0 | Async | n/a | MD/DO | Cash | $49 one-time consult |
| Evernow A menopause telehealth provider offering hormone therapy with ongoing clinician messaging. | 8.7 | Hybrid | n/a | MD/DO + NP/PA | Yes | $35/mo |
| Midi Health A telehealth clinic for perimenopause and menopause care, offering hormone therapy and non-hormonal treatment with insurance billing. | 8.3* | Video | — | MD/DO + NP/PA | Yes | $250 first visit self-pay |
 Defy Medical Also offers One of the longest-running hormone telehealth clinics, offering TRT, HRT for women, peptide therapy and sexual health treatments with physician oversight. | 6.9* | Video | Extra | MD/DO + NP/PA | Cash | Under $175/mo average for TRT in year one |
 Joi A women’s hormone telehealth clinic, sister brand to Blokes, offering HRT, peptide therapy and GLP-1 weight loss. | 6.2* | Hybrid | Extra | — | Cash | $149 hormone lab panel |
Head-to-head comparisons
Tools for this decision
What these clinics prescribe
Reference records for the compounds offered in this category. Mechanism, dosing ranges, evidence level and regulatory status for each.
- hCG — A placental glycoprotein hormone that mimics LH directly at the testis, the long-standing standard for preserving fertility on TRT.
- PT-141 — A melanocortin-4 selective agonist approved for hypoactive sexual desire disorder, acting centrally rather than vascularly.
- Semaglutide — A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss.
- Sermorelin — The first 29 amino acids of endogenous growth-hormone-releasing hormone, and the shortest fragment that retains full biological activity.
References
Regulatory and primary sources
- The Menopause Society ↗ · hormone therapy position statements
- FDA: Menopause and hormone therapy ↗ · approved products and labeling
- HHS: Telehealth for patients ↗ · what to expect from a telehealth visit
- FDA: BeSafeRx, buying medicine online safely ↗ · how to check an online pharmacy
- NABP: Safe.Pharmacy verified websites ↗ · pharmacy accreditation lookup
- FSMB DocInfo: physician license lookup ↗ · check a prescriber is licensed
- FTC: Endorsements, influencers and reviews ↗ · disclosure rules for affiliate links
Published literature
- A Contemporary View of Menopausal Hormone Therapy.Obstet Gynecol 2024.PubMed 38484309 · doi:10.1097/AOG.0000000000005553
- Menopausal hormone therapy for breast cancer patients: what is the current evidence?.Menopause 2026.PubMed 41025376 · doi:10.1097/GME.0000000000002627
- Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?.Circulation 2023.PubMed 36780393 · doi:10.1161/CIRCULATIONAHA.122.061559
- Menopausal hormone therapy and women's health: An umbrella review.PLoS Med 2021.PubMed 34339416 · doi:10.1371/journal.pmed.1003731
- Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.Front Endocrinol (Lausanne) 2021.PubMed 33841322 · doi:10.3389/fendo.2021.564781
- Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review.Int J Mol Sci 2025.PubMed 41303580 · doi:10.3390/ijms262211098
- The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis.BMC Womens Health 2024.PubMed 38263123 · doi:10.1186/s12905-023-02788-0
- Menopausal hormone therapy for the management of osteoporosis.Best Pract Res Clin Endocrinol Metab 2021.PubMed 34119418 · doi:10.1016/j.beem.2021.101551
Literature retrieved from PubMed on October 18, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.